{"id":820,"date":"2024-08-07T21:34:17","date_gmt":"2024-08-07T13:34:17","guid":{"rendered":"https:\/\/flcube.com\/?p=820"},"modified":"2024-10-14T09:41:13","modified_gmt":"2024-10-14T01:41:13","slug":"merck-kgaa-posts-1-7-q2-growth-amid-varied-business-segment-performance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=820","title":{"rendered":"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance"},"content":{"rendered":"\n<p>Merck KGaA (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:FRA\">FRA: MRK<\/a>) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to \u20ac5.4 billion (USD 5.9 billion) over the three-month period. The company&#8217;s performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in constant exchange rate terms to \u20ac2.258 billion. In contrast, Healthcare saw growth of 5.3% year-on-year, reaching \u20ac2.137 billion, and Electronics expanded by 7.6% to \u20ac957 million.<\/p>\n\n\n\n<p>The Life Sciences segment has been impacted by challenging macroeconomic conditions, particularly in the Asia-Pacific region during Q2\u201924. Despite this, the Healthcare business found growth drivers in key products such as Erbitux (cetuximab) for colorectal and head and neck cancer, which saw sales increase by 8.2% to \u20ac276 million; Mavenclad (cladribine) for multiple sclerosis, with a 6.5% year-on-year rise to \u20ac266 million; and Glucophage (metformin) for type 2 diabetes, benefiting from a 23.5% year-on-year global sales increase to \u20ac238 million due to the recovery in the Chinese market following the easing of pandemic restrictions.<\/p>\n\n\n\n<p>In response to these results, Merck has raised its forecast for the Group as well as for the Healthcare and Electronics business sectors. For the full 12-month period, the group anticipates net sales to range from \u20ac20.7 billion to \u20ac22.1 billion, with organic growth projected between +2% to +5%.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1203,120],"class_list":["post-820","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-fra-mrk","tag-merck"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to \u20ac5.4 billion (USD 5.9 billion) over the three-month period. The company&#039;s performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in constant exchange rate terms to \u20ac2.258 billion. In contrast, Healthcare saw growth of 5.3% year-on-year, reaching \u20ac2.137 billion, and Electronics expanded by 7.6% to \u20ac957 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=820\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=820\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-07T13:34:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T01:41:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=820#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=820\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance\",\"datePublished\":\"2024-08-07T13:34:17+00:00\",\"dateModified\":\"2024-10-14T01:41:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=820\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"FRA: MRK\",\"Merck\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=820#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=820\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=820\",\"name\":\"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-07T13:34:17+00:00\",\"dateModified\":\"2024-10-14T01:41:13+00:00\",\"description\":\"Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to \u20ac5.4 billion (USD 5.9 billion) over the three-month period. The company's performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in constant exchange rate terms to \u20ac2.258 billion. In contrast, Healthcare saw growth of 5.3% year-on-year, reaching \u20ac2.137 billion, and Electronics expanded by 7.6% to \u20ac957 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=820#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=820\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=820#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance - Insight, China&#039;s Pharmaceutical Industry","description":"Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to \u20ac5.4 billion (USD 5.9 billion) over the three-month period. The company's performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in constant exchange rate terms to \u20ac2.258 billion. In contrast, Healthcare saw growth of 5.3% year-on-year, reaching \u20ac2.137 billion, and Electronics expanded by 7.6% to \u20ac957 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=820","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=820","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-07T13:34:17+00:00","article_modified_time":"2024-10-14T01:41:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=820#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=820"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance","datePublished":"2024-08-07T13:34:17+00:00","dateModified":"2024-10-14T01:41:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=820"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","FRA: MRK","Merck"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=820#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=820","url":"https:\/\/flcube.com\/?p=820","name":"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-07T13:34:17+00:00","dateModified":"2024-10-14T01:41:13+00:00","description":"Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to \u20ac5.4 billion (USD 5.9 billion) over the three-month period. The company's performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in constant exchange rate terms to \u20ac2.258 billion. In contrast, Healthcare saw growth of 5.3% year-on-year, reaching \u20ac2.137 billion, and Electronics expanded by 7.6% to \u20ac957 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=820#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=820"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=820#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=820"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/820\/revisions"}],"predecessor-version":[{"id":6306,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/820\/revisions\/6306"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}